Send us Feedback

AstraZeneca (AZN)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW

 
Annual Reports

 
Other

AstraZeneca 20-F 2009

Documents found in this filing:

  1. 20-F
  2. Ex-7.1
  3. Ex-8.1
  4. Ex-12.1
  5. Ex-12.2
  6. Ex-13.1
  7. Ex-15.1
  8. Graphic
  9. Graphic
  10. Graphic
  11. Graphic
  12. Graphic
  13. Graphic
  14. Graphic
  15. Graphic
  16. Graphic
  17. Graphic
  18. Graphic
  19. Graphic
  20. Graphic
  21. Graphic
  22. Graphic
  23. Graphic
  24. Graphic
  25. Graphic
  26. Graphic
  27. Graphic
  28. Graphic
  29. Graphic
  30. Graphic
  31. Graphic
  32. Graphic
  33. Graphic
  34. Graphic
  35. Graphic
  36. Graphic
  37. Graphic
  38. Graphic
  39. Graphic
  40. Graphic
  41. Graphic
  42. Graphic
  43. Graphic
  44. Graphic
  45. Graphic
  46. Graphic
  47. Graphic
  48. Graphic
  49. Graphic
  50. Graphic
  51. Graphic
  52. Graphic
  53. Graphic
  54. Graphic
  55. Graphic
  56. Graphic
  57. Graphic
  58. Graphic
  59. Graphic
  60. Graphic
  61. Graphic
  62. Graphic
  63. Graphic
  64. Graphic
  65. Graphic
  66. Graphic
  67. Ex-15.2
  68. Ex-15.3
  69. Ex-15.4
  70. Graphic
  71. Graphic
  72. Graphic
  73. Graphic
  74. Graphic
  75. Graphic
  76. Graphic
  77. Ex-15.5
  78. Graphic
  79. Graphic
  80. Graphic
Exhibit 13.1
 
 
CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
(SUBSECTIONS (a) and (b) OF SECTION 1350, CHAPTER 63 OF TITLE 18, UNITED STATES CODE)
 
The certification set forth below is being submitted in connection with the Annual Report on Form 20-F for the year ended December 31, 2008 (the “Report”) for the purpose of complying with Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 (the “Exchange Act”) and Section 1350 of Chapter 63 of Title 18 of the United States Code.
 
David R. Brennan, the Chief Executive Officer and Simon Lowth, the Chief Financial Officer of AstraZeneca PLC, each certify that, to the best of his knowledge:
 
 
1.
the Report fully complies with the requirements of Section 13(a) or 15(d) of the Exchange Act; and
 
 
2.
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of AstraZeneca PLC.
 

March 17, 2009
        
           
           
/s/ David R. Brennan    
 
  
David R. Brennan    
 
  
Chief Executive Officer, AstraZeneca PLC    
 
  
 
           
/s/ S. Lowth    
 
  
S. Lowth,    
 
  
Chief Financial Officer, AstraZeneca PLC    
 
  


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki